SHOMG Research Department offers a number of clinical trials to qualifying patients. Our current, actively enrolling clinical trials and studies are listed below.

For more information, please discuss your interest in participating in a clinical trial with your physician. You can also contact our office at (209)466-2626 and ask to be connected to the Research Department. Alternatively, email us at clinicaltrials@shomg.net with any questions regarding eligibility.

Head and Neck Cancer

GSK JADE 221530: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Brief Summary: The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma).

For more information regarding this trial: https://clinicaltrials.gov/study/NCT06256588

Triple Negative Breast Cancer

Gilead ASCENT-05: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Brief Summary: The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician’s choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

For more information regarding this trial: https://clinicaltrials.gov/study/NCT05633654

Non-Small Cell Lung Cancer

Mirati KRYSTAL-7: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation

Brief Summary: The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and who are candidates for first line treatment.

For more information regarding this trial: https://clinicaltrials.gov/study/NCT04613596

Observational (Blood Draw) Studies

Personalis B-STRONGER-I: CtDNA Based MRD Testing for NAC Monitoring in TNBC

Brief Summary: A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

For more information regarding this study: https://clinicaltrials.gov/study/NCT06230185

Boston Gene BEGIN: BostonGene and Exigent Genomic INsight

Brief Summary: The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.

For more information regarding this study: https://clinicaltrials.gov/study/NCT06272864

Coming Soon

Flatiron FH-PrwS-07-002: Pan-tumor MRD Study

Brief Summary: The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.

Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

For more information regarding this study: https://clinicaltrials.gov/study/NCT06605404

Please see your treating physician for eligibility for any clinical trial we offer or you may contact our research department below.

Pam Magnasco, RN
Clinical Research Nurse Coordinator
pmagnasco@shomg.net

For additional questions not relating to eligibility please contact:

Ashley Mussi
Clinical Regulatory Specialist
amussi@shomg.net